-
Insider Buys Of The Week: Andeavor, Corcept, Portola
Saturday, August 25, 2018 - 6:01pm | 613Read More...Insider buying can be an encouraging signal for potential investors. A couple of biotech companies saw notable buying last week. So did a oil and gas midstream company in the midst of a merger. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one...
-
UPDATE: Oppenheimer Initiates Coverage on Corcept Technologies
Friday, August 5, 2011 - 9:34am | 87Read More...Oppenheimer has initiated coverage on Corcept Therapeutics (NASDAQ: CORT), and has also published a report on the event. In the report, Oppenheimer wrote, "We are initiating coverage of Corcept Therapeutics with an Outperform rating. Our positive outlook and valuation of the stock is based on the...
-
Piper Jaffray Raises PT On Corcept Therapeutics To $7
Tuesday, June 7, 2011 - 7:41am | 27Read More...Piper Jaffray has raised the price target on Corcept Therapeutics (NASDAQ: CORT) from $6 to $7 and maintains its Overweight rating.
-
UPDATE: Piper Jaffray Raises PT on Corcept Therapeutics to $7
Monday, June 6, 2011 - 8:46am | 129Read More...Piper Jaffray is out with its report today on Corcept Therapeutics (NASDAQ: CORT), raising its PT from $6 to $7. In a note to clients, Piper Jaffray writes, "Corcept presented Phase III data for Corlux, the company's lead drug for Cushing's Syndrome, at the ENDO meeting on Saturday. We expect...
-
Piper Jaffray Raises PT On Corcept Therapeutics To $7
Monday, June 6, 2011 - 7:02am | 27Read More...Piper Jaffray has raised the price target on Corcept Therapeutics (NASDAQ: CORT) from $6 to $7 and maintains its Overweight rating.
-
Global Hunter Comments On Corcept's Corlux NDA Submission During Week Of April 11
Friday, April 1, 2011 - 8:56am | 123Read More...According to Global Hunter, Corcept Therapeutics (NASDAQ: CORT) announced its intent to submit an NDA for the use of CORLUX in Cushing's Syndrome to the FDA the week of April 11th, which is fairly in line with management's Q1:11 guidance and our expectations. Global Hunter reported that...
-
Piper Jaffray Comments On Corlux NDA Announcement (CORT)
Friday, April 1, 2011 - 7:27am | 284Read More...Corcept Therapeutics Inc. (NASDAQ: CORT) has announced plans to file their NDA for Corlux for the treatment of Cushing's syndrome during the week of April 11th, “in line with expectations,” Piper Jaffray reports. “The company plans to request a priority review, which could allow for a 4Q11 PDUFA....
